<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T01:08:49Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/15642" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/15642</identifier><datestamp>2026-10-18T20:30:29Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>To what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease?</dc:title><dc:creator>Aydin, Suleyman</dc:creator><dc:creator>Sahin, Ibrahim</dc:creator><dc:creator>Demirel, Ulvi</dc:creator><dc:creator>Aksoy, Aziz</dc:creator><dc:subject>Fatty Liver</dc:subject><dc:subject>Ghrelin</dc:subject><dc:subject>Humans</dc:subject><dc:subject>Intercellular Signaling Peptides and Proteins</dc:subject><dc:subject>Protease Inhibitors</dc:subject><dc:subject>Serpins</dc:subject><dc:subject>amino acid</dc:subject><dc:subject>apelin</dc:subject><dc:subject>apelin 36</dc:subject><dc:subject>aprotinin</dc:subject><dc:subject>benzylsulfonyl fluoride</dc:subject><dc:subject>caspase</dc:subject><dc:subject>gamma glutamyltransferase</dc:subject><dc:subject>kallikrein inhibitor</dc:subject><dc:subject>obestatin</dc:subject><dc:subject>proteinase inhibitor</dc:subject><dc:subject>unclassified drug</dc:subject><dc:subject>vaspin</dc:subject><dc:subject>apoptosis</dc:subject><dc:subject>biochemistry</dc:subject><dc:subject>blood analysis</dc:subject><dc:subject>disease course</dc:subject><dc:subject>gamma glutamyl transferase blood level</dc:subject><dc:subject>gastrointestinal tract</dc:subject><dc:subject>hormone blood level</dc:subject><dc:subject>human</dc:subject><dc:subject>letter</dc:subject><dc:subject>liver cirrhosis</dc:subject><dc:subject>nonalcoholic fatty liver</dc:subject><dc:subject>priority journal</dc:subject><dc:date>2011</dc:date><dc:type>Letter</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/15642</dc:identifier><dc:identifier>https://doi.org/10.1016/j.metabol.2011.01.015</dc:identifier><dc:identifier>1532-8600</dc:identifier><dc:language>en</dc:language><dc:relation>Metabolism: Clinical and Experimental</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/15642</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>